Monthly Archives: November 2021

Pfizer Inc. (PFE-$50.75, NYSE): Initial Analyst Modeling Suggests First Year Paxlovid Sales May Surpass $20 Billion US. Omicron Might Render that to Be a Conservative Estimate.

The head of drugmaker Moderna said that existing COVID-19 vaccines, in all likeliness, will prove to be less effective against the new Omicron variant causing worldwide concern. “There is no world, I think, where [the effectiveness] is the same level…

Posted in Open Blog

Grupo Comercial Chedraui (CHDRAUIB.MX- 41.46 ). The Transformative “US Centric” Purchase of Smart & Final is Only Partially Reflected in Q3 2021 Results.

Posted in Portfolio Model Subscription

Pfizer Inc.’s New Antiviral Cocktail to Combat Covid-19 Seems Likely to Turn the Tide on Hospitalizations. An Entire Industry Sector is Poised to Benefit Disproportionately as a Result.

Utilizing “off the shelf” research on SARS (Sudden Acute Respiratory Syndrome) era antivirals, Pfizer Inc (PFE-NYSE, $47.51) seems, more than likely, to have produced an elegant solution for a very pressing gap in the current approach to combatting Covid-19 infection.

Posted in Open Blog
Recent Comments